RSC Medicinal Chemistry



CORRECTION

View Article Online



Cite this: RSC Med. Chem., 2024, 15,

Correction: computational design, synthesis, and assessment of 3-(4-(4-(1,3,4-oxadiazol-2-yl)-1Himidazol-2-yl)phenyl)-1,2,4-oxadiazole derivatives as effective epidermal growth factor receptor inhibitors: a prospective strategy for anticancer therapy

Nilesh Raghunath Khedkar,†b Milind Sindkhedkar*a and Alex Joseph;b

Correction for 'Computational design, synthesis, and assessment of 3-(4-(4-(1,3,4-oxadiazol-2-yl)-1Himidazol-2-yl)phenyl)-1,2,4-oxadiazole derivatives as effective epidermal growth factor receptor inhibitors: a prospective strategy for anticancer therapy' by Nilesh Raghunath Khedkar et al., RSC Med. Chem., 2024, 15, 1626-1639, https://doi.org/10.1039/D4MD00055B

DOI: 10.1039/d4md90040e

rsc.li/medchem

The authors regret that the affiliation of one of the authors (Nilesh Raghunath Khedkar) was shown incorrectly in the original manuscript. The corrected affiliation is shown here.

The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.

^a Novel Drug Discovery & Development, Lupin Research Park, Lupin Ltd., Pune-412115, India. E-mail: milindsindkhedkar@lupin.com

b Department of Pharmaceutical Chemistry, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka-576104, India

[†] Research Scholar, Manipal Academy of Higher Education.

[‡] Deceased on 19th Dec 2023.